Want to see JP:4592 full AI Analyst Report?
Top Page
SanBio Co
(4592)
Select Model
Select Model
Rating:41Neutral
Price Target:
¥878.00
▼(-60.63% Downside)
Action:Reiterated
Date:06/20/26
The score is held down primarily by weak financial performance (no revenue, sustained losses, and heavy ongoing cash burn implying continued funding risk) and bearish technicals (price below all key moving averages with negative MACD). Valuation provides limited support given a negative P/E and no dividend data.
Positive Factors
Proprietary cell therapy platform
Owning a proprietary cell-based platform targeting neurological and other serious diseases creates durable R&D leverage. A platform approach can support multiple indications, raise entry barriers vs peers, and enable long-term value via sequential programs or partner/licensing deals if clinical proof is achieved.
Negative Factors
No commercial revenue
Absence of any product revenue means the company remains entirely dependent on development outcomes and external financing. Long-term viability and ability to scale depend on successful clinical results and commercialization, making fundamentals highly binary and outcome-driven over the coming months to years.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary cell therapy platform
Owning a proprietary cell-based platform targeting neurological and other serious diseases creates durable R&D leverage. A platform approach can support multiple indications, raise entry barriers vs peers, and enable long-term value via sequential programs or partner/licensing deals if clinical proof is achieved.
Read all positive factors
SanBio Co (4592) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥83.76B
Dividend YieldN/A
Average Volume (3M)2.08M
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue GrowthN/A
EPS Growth31.36%
CountryJP
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-41.94
Shares Outstanding78,058,880
10 Day Avg. Volume2,869,570
30 Day Avg. Volume2,080,090
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,575.00Price Target Upside-29.37% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-50.85
Revenue Forecast (FY)¥1.74B
SanBio Co Business Overview & Revenue Model
Company Description
SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has comp...
How the Company Makes Money
null...
SanBio Co Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jan 2026 | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -10.17M | -8.05M | -9.37M | -14.50M | -24.61M | -132.47M |
| EBITDA | -3.41B | -4.20B | -2.98B | -2.50B | -4.62B | -4.37B |
| Net Income | -3.15B | -3.84B | -2.88B | -2.64B | -5.56B | -4.68B |
Balance Sheet | ||||||
| Total Assets | 14.52B | 15.62B | 3.45B | 5.05B | 7.05B | 5.51B |
| Cash, Cash Equivalents and Short-Term Investments | 14.00B | 15.08B | 2.92B | 4.45B | 6.73B | 4.56B |
| Total Debt | 1.18B | 1.24B | 397.00M | 665.00M | 933.00M | 2.52B |
| Total Liabilities | 1.84B | 2.02B | 1.68B | 2.25B | 2.62B | 3.48B |
| Stockholders Equity | 12.68B | 13.60B | 1.76B | 2.79B | 4.43B | 2.04B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -3.84B | -3.62B | -4.79B | -7.46B | -6.61B |
| Operating Cash Flow | 0.00 | -3.81B | -3.62B | -4.78B | -7.45B | -6.57B |
| Investing Cash Flow | 0.00 | -231.04M | -4.27M | -19.03M | -10.10M | -66.26M |
| Financing Cash Flow | 0.00 | 16.01B | 2.10B | 2.38B | 9.46B | -1.47B |
SanBio Co Technical Analysis
Negative
2230.00
Price Trends
1476.72
Negative
1753.03
Negative
2024.13
Negative
Market Momentum
-123.66
Negative
40.34
Neutral
73.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4592, the sentiment is Negative. The current price of 2230 is above the 20-day moving average (MA) of 1082.00, above the 50-day MA of 1476.72, and above the 200-day MA of 2024.13, indicating a bearish trend. The MACD of -123.66 indicates Negative momentum. The RSI at 40.34 is Neutral, neither overbought nor oversold. The STOCH value of 73.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4592.
SanBio Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥24.93B | -33.43 | ― | ― | -11.11% | -187.80% | |
49 Neutral | ¥19.62B | -10.34 | ― | ― | ― | 6.10% | |
45 Neutral | ¥12.75B | -19.87 | ― | ― | -25.02% | -697.06% | |
43 Neutral | ¥33.75B | -10.55 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥9.16B | -8.19 | ― | ― | -62.06% | 7.56% | |
41 Neutral | ¥83.76B | -24.08 | -253.07% | ― | ― | 31.36% |
* Healthcare Sector Average
JP:4592
SanBio Co
1,073.00
-1,046.00
-49.36%
JP:4593
Healios KK
250.00
-177.00
-41.45%
JP:4599
StemRIM Inc.
313.00
11.00
3.64%
JP:4978
ReproCELL Inc.
130.00
-54.00
-29.35%
JP:7774
Japan Tissue Engineering Co., Ltd.
614.00
44.00
7.72%
JP:7776
CellSeed Inc.
233.00
-232.00
-49.89%
SanBio Co Corporate Events
SanBio Books Forex Gains and Deferred Taxes, Flagging Exchange-Rate Impact on Q1 Results
Jun 16, 2026
SanBio Co. reported that in the first quarter of the fiscal year ending January 31, 2027, it booked non-operating income of 177 million yen in foreign exchange gains tied mainly to foreign currency loans and receivables with a consolidated subsidi...
SanBio Narrows Quarterly Loss but Maintains Deep Full-Year Red-Ink Outlook
Jun 15, 2026
SanBio reported no operating revenue for the three months ended April 30, 2026, and narrowed its net loss attributable to owners of the parent to ¥836 million from ¥1,531 million a year earlier, reflecting continued investment in its pip...
SanBio Wins NHI Listing for High-Priced AKUUGO Cell Therapy in Japan
May 25, 2026
SanBio has secured National Health Insurance price listing in Japan for AKUUGO Suspension for Intracranial Implantation, a cell therapy for improving chronic motor paralysis associated with traumatic brain injury, with an NHI price set at ¥72...
SanBio Secures Japan NHI Price for AKUUGO and Narrows FY 2027 Loss Forecast
May 19, 2026
SanBio said Japan’s Central Social Insurance Medical Council has approved a proposed National Health Insurance price of ¥72,716,528, including tax, for AKUUGO Suspension for Intracranial Implantation to treat chronic motor paralysis fol...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.